ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".